Stay updated on Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page.

Latest updates to the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedAdded a Publication entry for the study: 'First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial' with PubMed attribution, including the author list and Naples, Italy affiliation.SummaryDifference0.2%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page revision entry was updated from v3.4.2 to v3.4.3. The change adds Revision: v3.4.3 and removes Revision: v3.4.2.SummaryDifference0.0%

- Check45 days agoChange DetectedThe page update adds a Gastric cancer tag and a new link to the Genetic and Rare Diseases Information Center in the Resources section, and it updates the revision from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check53 days agoChange DetectedFooter now displays Revision: v3.4.1, replacing v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check68 days agoChange DetectedIntroduced a glossary toggle and added QC-related metadata (Last Update Submitted that Met QC Criteria and Last Update Posted) with revision updated to v3.4.0. Removed the previous QC label (Last Update Submitted that met QC Criteria), the estimated Last Update Posted label, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

- Check76 days agoChange DetectedRevision: v3.3.4 was published, replacing the previous v3.3.3. No visible changes to the study details or page layout are indicated by the screenshot.SummaryDifference0.0%

Stay in the know with updates to Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page.